AbbVie Inc.
American pharmaceutical company headquartered in North Chicago, Illinois, producing drugs across a wide range of medical areas; sixth largest biomedical company by revenue with operations across 170+ countries.
Clinical Trials
4
4 active
Approvals
14
Total approvals
Agencies
3
Regulatory bodies
Founded
2012
Active, not recruiting
4
100.0%
- Shennon Biotechnologies raised $12 million in new financing, bringing total capital raised to $25 million since its founding in 2021. - The company appointed industry veteran Cyril Konto, M.D., as CEO, with founder Li Sun, Ph.D., moving to President and Chief Technology Officer. - ShennonBio disclosed three T-cell engager programs: SBT-121 for small cell lung cancer, SBT-201 for ovarian cancer and SBT-425 for hepatocellular carcinoma. - The financing supports advancement of the company's integrated discovery platform and its first T-cell engager candidates toward an IND filing and Phase 1 development.
- Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts. - The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act. - Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act. - The legal action follows a 2024 U.S. Supreme Court loss for PhRMA, which had challenged the Arkansas law as unconstitutional on behalf of several manufacturers.
- At ASRS 2026 in Montreal, durable treatment strategies for wet AMD dominated research, with gene therapy, intravitreal implant and optogenetic data presented across four days. - Ocular Therapeutix reported phase 3 SOL-1 results showing a single AXPAXLI injection maintained BCVA in 74.1% of patients at Week 36 versus 55.8% with monthly aflibercept. - Nanoscope Therapeutics presented 3-year REMAIN data showing durable BCVA gains of about 3 ETDRS lines with MCO-010 in retinitis pigmentosa, alongside a rolling BLA submission. - Belite Bio's phase 3 DRAGON trial of oral tinlarebant met its primary endpoint with a 36% reduction in retinal lesion growth versus placebo in Stargardt disease.
- Alembic Pharmaceuticals Limited received final FDA approval for its generic Levothyroxine Sodium Tablets USP across 12 different strengths from 25 mcg to 300 mcg. - The approved product is therapeutically equivalent to AbbVie's Synthroid and is indicated for treating hypothyroidism and as adjunct therapy in thyroid cancer management. - According to IQVIA data, the product represents an estimated US market size of $1.869 billion for the 12 months ending March 2026. - This approval brings Alembic's total ANDA approvals from the FDA to 239, comprising 220 final approvals and 19 tentative approvals.
- Recent clinical trial developments in Crohn's disease include positive Phase 2a data for Agomab's ontunisertib in fibrostenosing disease and completion of first cohorts for Onco3R's SIK3 inhibitor O3R-5671. - TREMFYA demonstrates durable remission at two years as the first IL-23 inhibitor with fully subcutaneous treatment regimen, while receiving EC approval for ulcerative colitis maintenance therapy. - Major pharmaceutical companies including AbbVie, Takeda, Johnson & Johnson, and Pfizer continue to drive innovation in Crohn's disease therapeutics through extensive clinical trial programs. - Merck expands its tulisokibart development program with Phase 2b trials in three additional immune-mediated inflammatory diseases, highlighting growing therapeutic options.
- The Delhi High Court upheld patent rejections in two separate pharmaceutical cases, reinforcing strict disclosure requirements and amendment limitations under Indian patent law. - In the University of California case, the court ruled that insufficient disclosure of recombinant Salmonella vaccine mutations violated mandatory requirements under Sections 10(4) and 10(5) of the Patents Act. - The AbbVie case established that converting method-of-treatment claims to broader product claims without disease-specific limitations constitutes impermissible scope enlargement under Section 59(1). - Both rulings emphasize that patent specifications must provide adequate working embodiments and that amendments cannot artificially broaden claims beyond original disclosure.
- A new report provides an overview of the global clinical trial landscape for cerebral palsy, including trial numbers and enrollment trends. - The review covers clinical trials by region, country (G7 & E7), phase, trial status, endpoint status, and sponsor type. - The report identifies prominent drugs in ongoing trials and key companies involved in cerebral palsy therapeutics. - It also analyzes unaccomplished trials and enrollment trends over the past five years, offering insights for strategic decision-making.
- Cerevel Therapeutics is developing Emraclidine (CVL-231), a novel oral M4 muscarinic receptor positive allosteric modulator, for treating dementia and psychosis in Alzheimer's disease. - The drug candidate represents a potential breakthrough in addressing neuropsychiatric symptoms of Alzheimer's disease, targeting the muscarinic acetylcholine receptor M4 through a unique mechanism of action. - As a subsidiary of AbbVie Inc., Cerevel is expanding its neuroscience portfolio, with Emraclidine development programs spanning multiple neurological conditions including schizophrenia and Alzheimer's-related disorders.
